Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

NCT00926107 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
9
Enrollment
OTHER
Sponsor class

Stopped The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment

Conditions

Interventions

Sponsor

Hellenic Cooperative Oncology Group